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CD300A AND CD300C ON PLASMACYTOID DENDRITIC CELLS ARE
DOWN-REGULATED BY TLR7 AND TLR9 LIGAND INDUCED TYPE I IN-
TERFERON
Hart, D.N.J.1, Clark, G.1, Ju, X.1, Zenke, M.2. 1Mater Medical Re-
search Institute, Brisbane, Queensland, Australia; 2 Institute for Biomed-
ical Engineering, Aachen, Germany.
Plasmacytoid dendritic cells (pDC) constitute a distinct popula-
tion of DC in the peripheral and secondary lymphoid organs. After
activation with the ligands for Toll-like receptors (TLRs), particu-
larly TLR7 and TLR9, pDC secrete large amounts of type I inter-
ferons and differentiate into mature DC, expressing co-stimulatory
molecules and other cytokines. New immunoregulatory molecules
on human pDC were sought and their regulation by TLR ligands as-
sessed by pDC gene expression profiling. We established that both
the CD300a and CD300c cell surface molecules are expressed by
pDC. Because CD300 molecules play important roles in regulating
immune responses, we investigated their contribution to pDC func-
tion in more detail. First, their down-regulation by CpG-ODN was
confirmed by real time PCR and RT-PCR for CD300a and CD300c.
Using the monoclonal antibody CMRF-35, to detect both CD300a
and CD300c, we demonstrated that both TLR7 and TLR9 ligands
down-regulated cell surface CD300a and CD300c. We showed
that exogenous IFN-a down-regulated CD300a/c expression in
pDC suggesting that the TLR ligands induced down-regulation of
CD300a/c might be an indirect effect. In subsequent experiments,
we added neutralizing antibody to IFN-a and found that it abolished
the CpG-ODN induced CD300a/c down-regulation.
The effect of CD300a and CD300c activation on the function of
pDC was investigated by cross-linking CMRF-35 on pDC. This
had no effect on CD80, CD83 and CD86 expression, but decreased
MHC-II expression. Significant reductions in pDC TNF-a and IL-
6 production occurred after CMRF-35 cross-linking, however, in
marked contrast, CpG-ODN induced IFN was increased in these
experiments. Thus the immune regulators CD300a and CD300c
regulate the cytokine production in pDC, whilst the pDC released
cytokines regulated the CD300a/c expression. This suggests that
CD300 molecules may play a pivotal role in fine tuning pDC driven
immune responses and may contribute to the pDC biology of allo-
geneic bone marrow transplantation.320
RECENT TRENDS IN UNRELATED DONOR STEM CELL TRANSPLANTA-
TION: A REPORT FROM THE ABMTRR
Nivison-Smith, I.1, Bradstock, K.F.2, Dodds, A.J.3, Ma, D.D.F.3,
Szer, J.4. 1ABMTRR, Darlinghurst, NSW, Australia; 2Westmead Hospi-
tal, Westmead, NSW, Australia; 3St Vincent’s Hospital, Darlinghurst,
NSW,Australia; 4RoyalMelbourneHospital, Parkville, Victoria, Australia.
Aim: To investigate and highlight recent trends among patients
undergoing allogeneic haematopoietic stem cell transplant
(HSCT) with unrelated donors (URD) in Australia and New Zea-
land.Methods:Patients were selected from the database of the Aus-
tralasian Bone Marrow Transplant Recipient Registry (ABMTRR).
Patients selected for this study had undergone HSCT with URD
between the years of 2001 and 2006. Results: A total of 891 alloge-
neic HSCT with URD were performed in the years 2001 to 2006.
The annual numbers have increased steadily, from 101 in 2001 to
172 in 2005 and 146 in 2006. A total of 257 HSCT (29%) involved
patients aged up to 15 years, and 634 (71%) involved patients aged
16 or over. Among paediatric transplants, 128 (50%) utilised cord
blood (including double cord), 96 (37%) utilised bone marrow
and 33 (13%), peripheral blood. The major indication for transplant
in paediatric HSCT was ALL (79, 31% of paediatric HSCT).
Among adult transplants, the stem cell source was peripheral blood
in 407 (64%), marrow in 188 (30%) and cord blood in 39 (6%). The
major indication for adult transplant was AML (228, 36% of adult
HSCT). The number of adult HSCT for patients aged 50 years
or over increased from 20 in 2001 to 39 in 2006. The number
of adult HSCT involving reduced intensity conditioning also
increased, from 11 in 2001 to 48 in 2005 and 30 in 2006.
Conclusions: The annual numbers of URD HSCT in Australasia
have increased steadily in recent years. Recent trends in practice in-clude increases in numbers of older patients and HSCT using re-
duced intensity conditioning. The ABMTRR is a valuable
national resource which provides accurate and timely information
on HSCT activity and outcome in these two countries.321
EFFICACY AND TOXICITY OF A CONDITIONING REGIMEN WITH 8-GY
TOTAL BODY IRRADIATION, FLUDARABINE AND CYCLOPHOSPHAMIDE
FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PEDIATRIC HEMATOLOGIC MALIGNANCIES
Yanagisawa, R.1, Nakazawa, Y.1, Sakashita, K.1, Tanaka, M.1,
Kamijo, T.2, Shiohara, M.1, Koike, K.1. 1Shinshu University School of
Medicine, Matsumoto, Japan; 2Chiba Cancer Center Research Institute,
Chiba, Japan.
We examined the efficacy and toxicity of a conditioning regimen
with fractionated 8-Gy total body irradiation, fludarabine, and cyclo-
phosphamide in allogeneic hematopoietic stem cell transplantation
(HSCT) for pediatric hematologic malignancies. Among a total of
22 children who received related or unrelated HSCT, ninewere trans-
planted with refractory disease and/or from HLA 2 or more-loci mis-
matched family donors. The Seattle grading system revealed that 18
patients had no regimen-related toxicity, whereas the remaining
patients had grade I gastrointestinal toxicity alone. According to the
National Cancer Institute Common Toxicity Criteria, Grade II or
higher toxicity in the liver, mucosa, and gastrointestinal tract among
eight organs was documented in approximately 10–35% of patients,
and was attributed to engraftment syndrome and/or acute graft-ver-
sus-host disease. None of the patients developed graft failure. The
estimated overall survival and leukemia-free survival (LFS) at 2 years
were 56.3% and 46.7%, respectively, in 10 patients with acute
lymphoblastic leukemia; 91.7% and 81.5%, respectively, in 12 pa-
tients with myeloid leukemia. The incidence of treatment-related
mortality was 5.3% at 2 years. It is possible that our preparative reg-
imen confers successful engraftment combined with minimized regi-
men-related toxicity, and a favorable LFS rate for children with
hematologic malignancies, especially for those with myeloid leukemia.322
ROLE OF RITUXIMAB FOR PROPHYLACTIC OR PREEMPTIVE THERAPY
OF EBV-DNA-emia AND THERAPY OF EBV-PTLD IN HSCT RECIPIENTS:
A SYSTEMATIC REVIEW
Styczynski, J.1, Einsele, H.2, de la Camara, R.3, Engelhard, D.4,
Reusser, P.5, Ward, K.N.6, Ljungman, P.7. 1Collegium Medicum
UMK, Bydgoszcz, Poland; 2University Hospital, Wuerzburg, Germany;
3Hospital de la Princesa, Madrid, Spain; 4Hadassah University Hospital,
Jerusalem, Israel; 5Basel University School of Medicine, Porrentruy,
Switzerland; 6University College London, London, United Kingdom;
7Karolinska University Hospital, Stockholm, Sweden.
Objective: To evaluate the role of rituximab for prevention and
treatment of posttransplant lymphoproliferative disorder (EBV-
PTLD) in HSCT recipients. DATA SOURCES: A PubMed search
(1966-September 2007) was conducted using the key words: EBV,
posttransplant lymphoproliferative disorder, stem cell transplanta-
tion, rituximab. References of relevant articles and abstracts from
recent hematology and stem cell transplantation scientific meetings
(2003–2007) were also reviewed. STUDY SELECTION AND
DATA EXTRACTION: Prospective and retrospective studies
identified from the data sources were evaluated, and all data deemed
relevant were included in this analysis. DEFINITIONS: Prophy-
laxis of EBV-DNA-emia (EBV reactivation) – rituximab given to se-
ropositive, EBV-DNA-negative patient (or when donor was
seropositive) to prevent EBV reactivation. Preemptive therapy – rit-
uximab given to an asymptomatic patient with EBV detected by
a screening assay. Treatment of PTLD – rituximab applied to a pa-
tient with an overt EBV-PTLD. Results: High risk HSCT for
PTLD development were allogeneic HSCT with following risk fac-
tors: unrelated/mismatch HSCT; T-cell depletion or ATG/OKT3
use; EBV serology mismatch; primary EBV infection; splenectomy.
The risk increased with the number of risk factors. In addition to
quantification of EBV DNA load, analysis of the level of EBV-spe-
cific T cell reconstitution during EBV reactivation might be an
